This study is looking at an Immunotherapy CARE Program to see if it helps people with kidney, bladder, breast, or lung cancer manage their immunotherapy treatment better. The program involves staff helping with essential needs and reporting side effects. You might be able to join if you are 18 or older, have one of these cancers, and are starting treatment with PD-1 or PD(L)-1 immune checkpoint inhibitors. The study will measure if participants continue their immunotherapy treatment for at least 6 months and will also look at how the program affects your quality of life through questionnaires. The study is currently unclear on its recruitment status and plans to enroll 200 people.

Study design

This is an interventional study with an unclear status, planning to enroll 200 participants.

What's involved

If assigned to the I CARE arm, CCNY staff will assist you monthly with essential needs and side effects/symptom reporting. You will also complete questionnaires to measure your quality of life.

Compensation

Not stated in the trial record.

Follow-up

The study measures immunotherapy continuation at 6 months, suggesting follow-up for at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.